FINWIRES · TerminalLIVE
FINWIRES

Clinuvel Pharmaceuticals Advances Nasdaq ADR Uplisting With US SEC Review Underway

By

-- Clinuvel Pharmaceuticals (ASX:CUV) said it is working with the US Securities and Exchange Commission (SEC) on its draft registration statement as it advances plans to uplist its American depositary receipt (ADR) program on the Nasdaq stock market, according to a Tuesday filing with the Australian bourse.

The company received four rounds of US SEC comments and expects the review process to be completed before the end of the fiscal year, after which it plans to upgrade its ADR program to level two from level one and list on Nasdaq under the revised ticker "CUVL," per the filing.

The company stated that the uplisting is still subject to regulatory approval and Nasdaq requirements, and that its success and timing are not guaranteed, the filing added.

Related Articles

Asia

Cambricon's Profit Soars 185% in Q1, Revenue Jumps 160% on AI Boom

Cambricon Technologies (SHA:688256) reported a 185% jump in attributable net profit in the first quarter of 2026 to 1.01 billion yuan from 355.5 million yuan.Earnings per share nearly tripled to 2.38 yuan from 0.85 yuan, according to a Shanghai Stock Exchange filing on Thursday.The Chinese semiconductor company's revenue surged 160% to 2.88 billion yuan from 1.11 billion yuan a year prior, which it attributed to the continued surge in computing power demand from the artificial intelligence industry.

$SHA:688256
Asia

Update: ANZ Group Holdings Posts Higher Fiscal H1 Cash Earnings, Operating Income

(Updates to add stock movement in the last paragraph)ANZ Group Holdings (ASX:ANZ, NZE:ANZ) reported Friday fiscal first-half cash earnings of AU$1.242 per share, up from AU$1.17 a year earlier.Analysts polled by FactSet expected earnings of AU$1.23.Operating income for the six months ended March 31 was AU$11.2 billion, compared with about AU$11 billion a year earlier. Analysts surveyed by FactSet expected AU$11.39 billion.The board declared an interim dividend of AU$0.83 per share, unchanged from the prior corresponding period, payable July 1 to shareholders on record as of May 12.The company's shares on the Australian and New Zealand bourses fell around 1% and 2%, respectively, in recent Friday trade.

$ASX:ANZ$NZE:ANZ
Asia

Larvotto Resources Shares Up As New South Wales Antimony-Gold Project Plant Refurbishment Works Progress

Larvotto Resources' (ASX:LRV) shares rose 1% in recent trading on Friday after it said late on Thursday that plant refurbishment works at the Hillgrove antimony-gold project in New South Wales were advancing on schedule and on budget, with commissioning expected in the middle of the year.Equipment from the processing plant, including tanks, pumps, and hydraulic drives, was removed, disassembled, and dispatched for refurbishment to various service providers. Primary and secondary crusher refurbishment is nearing completion.Induced polarization surveys were completed at the project, with results used to generate new drill targets.

$ASX:LRV